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Background: The ESHOL study showed that post-dilution online hemodiaﬁltration (OL-HDF)
reduces all-cause mortality versus hemodialysis. However, during the observation period,
355 patients prematurely completed the study and, according to the study design, these
patients were censored at the time of premature termination.
Methods: The aim of this study was to investigate the outcome of patients who discontinued
the  study.
Results: During follow-up, 207 patients died while under treatment and 47 patients diedIntention to treat
On-line hemodiaﬁltration
Survival
after  discontinuation of the study. Compared with patients maintained on hemodialysis,
those randomized to OL-HDF had lower all-cause mortality (12.4 versus 9.46 per 100 patient-
years, hazard ratio and 95% CI: 0.76; [0.59 to 0.98], P = 0.031). For all-cause mortality by
time-dependent covariates and competing risks for transplantation, the time-dependent
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Cox analysis showed very similar results to the main analysis with a hazard ratio of 0.77
(0.60 to 0.99, P = 0.043).
Conclusion: The results of this analysis of the ESHOL trial conﬁrm that post-dilution OL-HDF
reduces all-cause mortality versus hemodialysis in prevalent patients. The original results
of  the ESHOL study, which censored patients discontinuing the study for any reason, were
conﬁrmed in the present ITT population without censures and when all-cause mortality
was considered by time-dependent and competing risks for transplantation.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Reanálisis  del  estudio  ESHOL:  mortalidad  por  todas  las  causas
considerando  riesgos  de  competición  y  tiempo-dependientes  para
trasplante  renal
Palabras clave:
Terapias convectivas
Intención de tratar
Hemodiaﬁltración on-line
Supervivencia
r  e  s  u  m  e  n
Introducción: El estudio ESHOL ha demostrado que la hemodiaﬁltración on line (HDF-OL)
posdilución reduce la mortalidad por todas las causas respecto a la hemodiálisis (HD)
en  pacientes prevalentes. Sin embargo, durante el periodo de observación, 355 pacientes
ﬁnalizaron prematuramente el estudio, de acuerdo con el disen˜o del mismo.  Estos pacientes
fueron censurados en el momento de la ﬁnalización prematura.
Objetivos: El objetivo de este estudio fue investigar los eventos de los pacientes que aban-
donaron el estudio.
Métodos: Reanalizar los datos de supervivencia utilizando la población por intención de
tratar en los 3 an˜os de seguimiento. Los datos fueron analizados considerando también
el  trasplante renal como evento competitivo de la muerte del paciente.
Resultados: Durante el seguimiento, 207 pacientes fallecieron durante el tratamiento y 47
después de abandonar el estudio. Comparados con aquellos pacientes que se mantuvieron
en  HD, los que fueron aleatorizados a HDF-OL tuvieron una mortalidad total menor (12,4 vs.
9,46 por 100/pacientes/an˜o, hazard ratio [HR] e IC 95%: 0,76 [0,59-0,98]; p = 0,031). La mortali-
dad  total por todas las causas, teniendo en consideración el riesgo competitivo del trasplante
renal  y tiempo-dependiente, mostró en el análisis de Cox tiempo-dependiente resultados
similares al análisis principal con un HR de 0,77 (0,60-0,99; p = 0,043).
Conclusiones: Los resultados del reanálisis del estudio ESHOL se conﬁrman cuando se aplica
el  análisis en la población por intención de tratar sin censurar ninguna observación y
considerando la mortalidad por todas las causas dependiente del tiempo y del riesgo com-
petitivo del trasplante renal.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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he “On-Line Hemodiaﬁltration Survival Study” [Estudio de
upervivencia de Hemodiaﬁltración On-Line’ (ESHOL)]1 showed
hat high-efﬁciency post-dilution OL-HDF reduces all-cause
ortality versus conventional hemodialysis (HD) in prevalent
hronic dialysis patients. The inferential analysis of the main
ariable, time to occurrence of any event, deﬁned as all-cause
ortality (overall survival), was estimated from the unad-
usted Cox model with no imputation by means of the log-rank
est for the between-treatment comparison and hazard ratios
HR) with their 95% conﬁdence intervals. The study provided detailed description of the time and causes of censoring to
ule out any potential biases. However, during the observa-
ion period, 355 patients prematurely ﬁnished the study and,(http://creativecommons.org/licenses/by-nc-nd/4.0/).
according to the study design, all these patients were censored
at the time of premature termination. Most studies conducted
in hemodialysis patients (the Hemodialysis (HEMO) study,2 the
Membrane Permeability Outcome (MPO) study,3 the Turkish
HDF study4) have been performed with this method, given that
a high percentage of patients could be excluded mainly due to
renal transplantation.
In randomized clinical trials (RCT), it is recommended
that data be analyzed by an intention-to-treat (ITT) analy-
sis, which compares outcomes according to the initial random
allocation, regardless of which intervention the patients actu-
ally received. ITT is recommended as the method of choice
for analysis in trials investigating the superiority of an
intervention.5–7 Among studies comparing OL-HDF with HD,
only the CONTRAST study8 used ITT to analyze the primary
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endpoint. This kind of analysis avoids various misleading arti-
facts that can arise in intervention research, such non-random
attrition of participants from the study. Importantly, a non-ITT
analysis may lose the beneﬁts of randomization, as the groups
may no longer be balanced with regard to factors inﬂuencing
the outcome.9,10 In the ESHOL study,1 164 patients were cen-
sored in the HD arm and 191 patients in the OL-HDF arm. As
expected, renal transplantation was the main cause of censor-
ing (79 in the HD arm and 101 in the OL-HDF arm). In survival
analysis conducted to analyze the risk of death in dialysis
patients, renal transplantation is a well-known competing risk
because, after transplantation, patients will no longer be on
dialysis and, therefore, will not be at risk of dying on dialysis.
In this setting, the competing event, i.e. kidney transplanta-
tion, hinders the occurrence of the event of interest. Different
approaches have been proposed to overcome this difﬁculty,
but the best option is to conduct a full ITT analysis after com-
pletion of follow-up for censored observations for any reason
in order to evaluate the risk of death for censored observations
from both arms of the trial.
The aim of this study was to investigate the outcome of
patients who  discontinued the ESHOL study and to re-analyze
survival data by using the ITT population with a 3-year follow-
up. We  also performed a sensitivity analysis using the ITT
population. Finally, we  analyzed our data, considering renal
transplantation as a competing event to patient death.
Patients  and  methods
General  methods  and  patients
The design and methods of the ESHOL study have previously
been reported.11 Brieﬂy, the ESHOL study was a prospective,
randomized, open-label clinical trial in patients with end-
stage renal disease under hemodialysis in Catalonia (Spain).
The registered protocol number is NCT00694031.12
The primary objective was to assess the effect of post-
dilution OL-HDF compared with hemodialysis on all-cause
mortality. The primary outcome variable was the time to the
occurrence of death from any cause. Key secondary outcomes
were cardiovascular mortality and other causes of mortality.
Study  population
The study population has been previously described.1,11
Essentially, the inclusion criteria consisted of patients older
than 18 years with end-stage renal disease receiving thrice-
weekly standard hemodialysis for more  than 3 months.
Exclusion criteria were as follows: active systemic diseases,
liver cirrhosis, malignancy, immunosuppressive therapy,
inadequate dialysis dose (single pool Kt/V < 1.3), single-needle
dialysis and the use of temporary non-tunneled catheters.
Randomization  and  dialysis  treatment  parametersPatients were randomized 1:1 to continue on thrice weekly
hemodialysis or to start OL-HDF 3 times a week. The length
of the recruitment period was 16 months and the study was;3 6(2):156–163
completed to provide a complete follow-up until patient death
or 3 years for all surviving patients.
Treatment  procedures
Both OL-HDF and hemodialysis were performed with ultra-
pure dialysis ﬂuids and the length of dialysis sessions in each
treatment modality was not modiﬁed. For patients on post-
dilution OL-HDF, a minimum of 18 L/session of replacement
volume was requested. Patients not receiving the allocated
treatment modality for more  than 2 consecutive months were
withdrawn from the study.
Censored  observations
In the original study, patients were observed until each
enrolled patient completed 3 years of follow-up, until prema-
ture termination, or until death. In the original study, 355 out
of 906 patients (39.2%) with premature termination were cen-
sored before completing the 3-year follow-up. For the present
study, the principal investigators at each participating center
were contacted to provide information on survival status at
3 years for each censored observation. Each principal inves-
tigator contacted the renal transplant unit where patients
received a kidney transplant or other hemodialysis facilities
where the patients were receiving treatment from the time of
censoring. The date and cause of death for each participating
patient censored during the study were recorded to calculate
patient survival in the ITT population.
Statistical  analysis
All-cause mortality, as well as cardiovascular death, cachexia,
infection, tumors, sudden death and death from other causes
were described by means of the Kaplan–Meier method. The
log-rank test was used for hypothesis testing, and the hazard
ratio and its 95% conﬁdence interval (95% CI) were estimated
from the unadjusted Cox model. Additional multivariate Cox
regression sensitivity analyses were conducted with adjust-
ment by age, gender, diabetes, the Charlson comorbidity
index (the original scale and also excluding diabetes) and the
type of vascular access. Time-dependent Cox analysis, which
included the time of transplantation13 as well as the cumu-
lative incidence curves of progression in a competing risks
framework, with transplantation without death as a compet-
ing event,14,15 were also assessed to check the robustness of
the study results.
Two-sided signiﬁcance tests were used throughout, and a
P-value of <0.05 was considered signiﬁcant. All statistical anal-
yses were performed using the SAS 9.2 statistical package.
Results
Outcome  of  censored  observationsOf 906 patients included in the randomization, 355 (39.18%)
prematurely discontinued the study because of kidney trans-
plantation (n = 180, 19.87%), change of dialysis unit (n = 58,
6.40%), organizational changes (n = 33, 3.64%), withdrawal of
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Table 1 – Mortality of the 355 patients that discontinued study.
Outcome HD group (n = 164) OL-HDF group (n = 191) Hazard ratio [95% CI] P value*
Patient-years at risk 470.6 531.8
No. of
events
No. of
events/100
patient-yr
No. of
events
No. of
events/100
patient-Yr
Death from any cause 19 4.04 28 5.27 1.38 [0.76 to 2.49] 0.285
Cardiovascular cause 6 1.28 10 1.88 1.78 [0.61 to 5.21] 0.285
Heart failure 2 0.43 1 0.19 0.44 [0.04 to 4.9] 0.496
Ischemic heart disease 1 0.21 3 0.56 2.7 [0.28 to 26] 0.369
Mesenteric trombosis 0 0.00 0 0.00 NA NA
Stroke 2 0.43 5 0.94 2.22 [0.43 to 11.47] 0.326
Dysrhythmia 1 0.21 0 0.00 NA NA
Peripheral arteriopathy 0 0.00 1 0.19 NA 0.352
Infection 5 1.06 6 1.13 1.06 [0.32 to 3.48] 0.919
Tumor 3 0.64 2 0.38 0.59 [0.10 to 3.52] 0.557
Sudden death 0 0.00 5 0.94 NA 0.036
Cachexia 2 0.43 2 0.38 0.91 [0.13 to 6.43] 0.921
Death from other causes 3 0.64 3 0.56 0.87 [0.18 to 4.32] 0.868
HD denotes hemodialysis, and OL-HDF on-line hemodiaﬁltration.
∗ P value by the log-rank test.
Table 2 – Revison of deaths of patients that discontinued study in relation to discontinued cause.
Outcome HD group (n = 164) OL-HDF group (n = 191) Hazard ratio [95% CI] P value*
Patient-years at risk 470.6 531.8
No. of
events/n
No. of
events/100
patient-yr
No. of
events/n
No. of
events/100
patient-yr
Renal transplant 2/79 0.43 9/101 1.69 3.63 [0.78 to 16.79] 0.078
Change of HD center 3/25 0.64 7/33 1.32 2.70 [0.56 to 13.00] 0.197
Organizational changes 6/20 1.28 2/13 0.38 0.50 [0.10 to 2.49] 0.390
Withdrawal of consent 2/12 0.43 3/15 0.56 1.35 [0.22 to 8.07] 0.744
Temporary catheter 1/8 0.21 3/11 0.56 2.55 [0.26 to 24.62] 0.401
Change of treatment 2/8 0.43 1/7 0.19 0.55 [0.05 to 6.07] 0.620
Other reasons 3/12 0.64 3/11 0.56 1.17 [0.24 to 5.82] 0.845
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aHD denotes hemodialysis, and OL-HDF on-line hemodiaﬁltration.
∗ P value by the log-rank test.
onsent (n = 27, 2.98%), need for a temporary catheter (n = 19,
.10%), change of treatment (n = 15, 1.66%) or other, non-
redeﬁned reasons (n = 23, 2.54%). In the present analysis, a
-year follow-up was completed for all these patients with a
remature termination. At 3 years, 305 patients were alive, 47
atients had died and only 3 patients were censored prema-
urely on the last date when known to be alive. Thus, the mean
ollow-up was 2.6 ± 0.8 years and the median observation time
or censored patients was 3.0 years. Mortality after discontin-
ation of the study was similar in both groups: 4.04 per 100
atient-year in the HD arm and 5.27 per 100 patient-year in the
L-HDF arm. The causes of mortality in discontinued patients
n each arm are described in Table 1. There were no signiﬁcant
ifferences in the death rate in the 2 arms of the trial according
o the causes of patient discontinuation (Table 2).ll-cause  mortality  in  the  intention-to-treat  population
uring the 3-year follow-up, 207 patients died on treatment
nd 47 patients died after discontinuation of the study; thus,254 out of 906 patients died (28.03%) during follow-up, with a
3-year all-cause mortality rate of 24.78% and 31.33% in the OL-
HDF and the HD groups, respectively. Kaplan–Meier survival
curves with the ITT population with only 3 censored patients
showed that patient survival was lower in patients allocated to
the HD arm than in those allocated to OL-HDF arm (log-rank
P = 0.031) (Fig. 1). Univariate Cox regression analysis showed
that patients allocated to the OL-HDF group had a 24% risk
reduction (hazard ratio [95% CI]: 0.76 [0.59 to 0.98]; P = 0.031)
for mortality for any cause (Table 3). The main causes of death
were cardiovascular diseases (42.5%) and infectious diseases
(16.9%) and there were no signiﬁcant differences between
groups (Table 3).
Sensitivity  analysisSensitivity analyses were performed on the basis of the follow-
ing variables, which were found to be independent predictors
for all-cause mortality: age, gender, diabetes, the Charlson
comorbidity index and vascular access. These variables were
160  n e f r o l o g i a. 2 0 1 6;3 6(2):156–163
Table 3 – Primary outcome. Mortality (ITT).
Outcome HD group (n = 450) OL-HDF Group (n = 456) Hazard ratio [95% CI] P value*
Patient-years at risk 1138.0 1194.4
No. of
events
No. of
events/100
patient-yr
No. of
events
No. of
events/100
patient-yr
Death from any cause 141 12.39 113 9.46 0.76 [0.59 to 0.98] 0.031
Cardiovascular cause 61 5.36 47 3.93 0.73 [0.50 to 1.07] 0.107
Heart failure 12 1.05 8  0.67 0.63 [0.26 to 1.53] 0.302
Ischemic heart disease 16 1.41 17 1.42 1.01 [0.51 to 1.99] 0.982
Mesenteric trombosis 6 0.53 5 0.42 0.80 [0.24 to 2.62] 0.709
Stroke 20 1.76 12 1.00 0.57 [0.28 to 1.17] 0.122
Dysrhythmia 6 0.53 3 0.25 0.48 [0.12 to 1.92] 0.289
Peripheral arteriopathy 1 0.09 2 0.17 1.89 [0.17 to 20.88] 0.596
Infection 27 2.37 16 1.34 0.56 [0.30 to 1.05] 0.065
Tumor 9 0.79 12 1.00 1.27 [0.53 to 3.00] 0.592
Sudden death 14 1.23 19 1.59 1.29 [0.65 to 2.57] 0.470
Cachexia 10 0.88 6 0.50 0.57 [0.21 to 1.58] 0.276
Death from other causes 20 1.76 13 1.09 0.62 [0.31 to 1.24] 0.172
HD denotes hemodialysis, and OL-HDF on-line hemodiaﬁltration.
∗ P value by the log-rank test.
Fig. 1 – Kaplan–Meier curves for 36-month survival in the
intention-to-treat population (P = 0.031 by the log-rank test).
HD denotes hemodialysis, and OL-HDF, on-line
hemodiaﬁltration.
included in 3 different multivariate analyses to assess the
covariate-adjusted risk estimates for the intervention (Fig. 2).
When these covariates were included, the effect of treatment
was on the verge of signiﬁcance (model I). In model II, renal
transplantation was added to model I as a time-dependent
covariate and the adjusted risk estimate for the intervention
was identical to model I. Finally, in model III, an adjusted risk
estimate was done considering renal transplantation as the
only cause for censoring. The treatment risk estimates were
also calculated in all subgroups arising from these variables,
using the original categories for nominal variables and tertiles
for continuous variables. All hazard ratios were consistent for
both types of analysis and the statistical tests for interaction
were not signiﬁcant (Fig. 2). In this analysis, male and older
(upper tertile of age) patients, as well as patients in the upper
tertile of the Charlson comorbidity index, obtained signiﬁcant
beneﬁt from the intervention.All-cause  mortality  by  time-dependent  and  competing
risks for  transplantation
Since the underlying risk of death is known to change after
transplantation, we modeled all-cause mortality taking into
account the time of transplantation in a time-dependent
approach. The time-dependent Cox analysis (Fig. 2) showed
very similar results to the main analysis with a hazard ratio
[95% CI] of 0.77 [0.60 to 0.99] (P = 0.043).
Survival analysis was repeated to assess the consistency of
the results by considering renal transplantation as a compet-
ing event and consequently death after transplantation was
not considered. For the other patients discontinuing the study,
complete follow-up until 3 years was considered and events
occurring after discontinuation of the study were included.
Survival curves for both treatment groups are shown in Fig. 3,
conﬁrming that patients allocated to OL-HDF group had a
higher survival than patients allocated to the HD arm (Gray’s
test, P = 0.006).
Discussion
In the present study, we conducted a new analysis of the
ESHOL-study with the ITT population with a complete follow-
up for 3 years after trial enrollment. In the previous study,1
patients who were alive when they discontinued the study
for any reason were censored at the time of withdrawal. As
in other studies conducted in patients on hemodialysis, there
was a high rate of censored observations before 3 years (39.2%)
and the main reason for censoring was renal transplanta-
tion, accounting for more  than 50% of cases. Additionally,
the proportion of patients receiving a kidney transplant was
slightly higher in the HDF-OL arm than in the HD arm (101
out of 456 patients versus 79 out of 450 patients), suggest-
ing that, despite the randomized allocation of patients to both
arms, there may have been an unbalanced risk between the 2
groups. In survival analyses, all subjects at risk of experiencing
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Fig. 2 – Sensitivity analyses for the main outcome showing hazard ratios [95% CI] for the intervention based on relevant
variables that were  found to be independent predictors for all-cause mortality. Multivariate I: age, gender, diabetes and
vascular access. Multivariate II: age, gender, diabetes, vascular access and the Charlson comorbidity index. Multivariate III:
age, gender, diabetes, vascular access, Charlson comorbidity index and censoring for transplantation. 1T, 2T and 3T: ﬁrst,
second and third tertiles.
a
c
c
s
s
t
p
t
c
s
k
t
t
s
p
yn event constitute the risk set. Standard survival analyti-
al methods such as the Kaplan–Meier method assume that
ensoring is “independent”, this is, that patients who are cen-
ored at a certain time point should be representative of those
till at risk (and, thus, in the risk set) at that time point. In
he ESHOL study, we  observed that censoring was not inde-
endent, since censored patients had a lower risk of death
han those continuing in the trial (the risk set). These results
ould be expected in hemodialysis patients who were cen-
ored mainly because of renal transplantation, since it is well
nown that the risk of death decreases after renal transplanta-
ion in chronic hemodialysis patients. Nevertheless, according
o the randomized design of the trial, the risk of death in cen-
ored patients in both arms of the trial was not different (4.04
er 100 patients-year in the HD arm and 5.27 per 100 patients-
ear in the HDF-OL arm).“Intention to treat” is a strategy to analyze randomized
controlled trials comparing patients according to the initial
random allocation. This is generally interpreted as including
all patients, regardless of whether they actually satisﬁed the
entry criteria, the treatment actually received, and subsequent
withdrawal or deviation from the protocol. The ITT approach
maintains treatment groups that are similar apart from ran-
dom variation and allows for non-compliance and deviations
from policy by clinicians.16 This approach characterizes the
effectiveness of the intervention and offers information on the
potential beneﬁt observed in clinical practice. If an ITT analy-
sis is not done, clinical effectiveness may be overestimated.17
In the ESHOL study, an ITT analysis was not originally
planned since we  expected a signiﬁcant percentage of with-
drawals (15% per year) and assumed that it would not affect
the main conclusions of our study. Indeed, other studies
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Fig. 3 – Kaplan–Meier curves for 36-month survival in
competitive risks cumulative incidence of death (Gray’s test,
P value = 0.006). HD denotes hemodialysis, and OL-HDF,
on-line hemodiaﬁltration.
conducted in hemodialysis patients to evaluate the beneﬁt of
different interventions were performed with a similar design.
To overcome this limitation and to gain further insight into
the effectiveness of our intervention, we  decided to conduct
the present study with a complete ITT analysis of the ESHOL
study. In the univariate analysis of the present study, we were
able to demonstrate that patients allocated to the OL-HDF arm
had a signiﬁcant 24% risk reduction of death compared with
patients allocated to the HD arm. Importantly, the death rate
was lower in this ITT population than in patients continuing
under hemodialysis. Thus, this new analysis is less powered
to detect a difference between groups. This loss of statistical
power partly explains why, after adjustment for age, gender,
diabetes, the Charlson comorbidity index and vascular access
in the multivariate analysis, the 20% risk reduction was only
on the threshold of signiﬁcance (P = 0.086).
Despite the usefulness of ITT analysis to analyze the ESHOL
study, the main reason for withdrawal was renal transplanta-
tion. This is a classic example of competing risk in nephrology
and, in this situation, it has been proposed that an alternative
way to analyze data is by a proportional cause-speciﬁc hazards
model with application of Cox regression analysis for each of
the speciﬁc event types.7 In each of these models, the compet-
ing events are treated as censored observations. We  have also
performed this analysis (model III of the sensitivity analysis)
and we  observed a statistically signiﬁcant 25% reduction in the
risk of death by adjusting for confounders in patients allocated
to the OL-HDF arm. Finally, the results of the 2 approaches to
assess the potential effect of transplantation on the results,
the time-dependent Cox analysis and the competing events
approach, both yielded similar results to that of the primary
raw analysis and conﬁrmed the positive conclusions of the
trial.
In the last year, 4 meta-analyses have been published
that analyze the effect of convective against diffusive
18–21 18therapies. Susantitaphong et al. evaluated randomized
controlled trials comparing the effect of convective therapies
including high-ﬂux dialysis, hemoﬁltration or hemodiaﬁl-
tration versus low-ﬂux dialysis. The 3 other most recent;3 6(2):156–163
meta-analyses19–21 that included all 3 RCT with mortality as
the primary endpoint1,4,8 to compare convective techniques
versus low- or high-ﬂux hemodialysis were positive in terms
of survival, but the results were inconclusive, probably due
to the disparity of criteria and confounding factors. Only the
meta-analysis of the EuDial working group,21 including only
RCT comparing OL-HDF versus hemodialysis (hemoﬁltration
and AFB were excluded) showed the superiority of OL-HDF to
HD on overall and cardiovascular mortality. The discrepancies
between these meta-analyses can be explained by the differ-
ent research questions, different selection criteria of clinical
trials and potential confounding factors (delivered dose of
convective therapy, pre- or postdilution infusion or treatment
modality). A revised deﬁnition of HDF was published by the
EuDial group,22 in which HDF is a blood puriﬁcation therapy
combining diffusive and convective solute transport using a
high-ﬂux membrane characterized by an ultraﬁltration coefﬁ-
cient greater than 20 mL/h/mmHg/m2 and a sieving coefﬁcient
for 2-microglobulin greater than 0.6; convective transport is
achieved by an effective convection volume of at least 20% of
the total blood volume processed. If these criteria were applied
when selecting the RCT for inclusion in meta-analyses, none
of the 4 published meta-analyses would meet them. It can
therefore be questioned whether these meta-analyses are
valid to answer the question of whether high-volume HDF
improves survival compared with hemodialysis.
In summary, the results of this reanalysis of the ESHOL
trial conﬁrm that high efﬁciency postdilution OL-HDF reduces
all-cause mortality versus conventional hemodialysis in
prevalent patients. These results are consistent indepen-
dently of the statistical analysis employed. The original results
observed in the ESHOL study, which censored patients dis-
continuing the study for any reason, were conﬁrmed in the
present study, which considered all-cause mortality in the ITT
population without censures and also considered all-cause
mortality by time-dependent and competing risks for trans-
plantation.
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Appendix.
The following institutions and investigators participated in
the ESHOL study:
CETIRSA, Barcelona: M. Pons, B. Insensé, C. Perez, T. Feliz;
Hospital San Antonio Abad, Vilanova i la Geltru:  R. Ramos, M. Bar-
betta, C. Soto; Fresenius Medical Care, Granollers:  J. Mora,  A. Juan,
O. Ibrik; Diaverum Baix Llobregat, Hospitalet:  A. Foraster, J. Car-
reras; Fresenius Medical Care, Hospitalet: F. Moreso, M. Hueso,
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. Nin, A. Fernández; Fresenius Medical Care, Reus: J. Soler, M.
rruche, C. Sánchez, J. Vidiella; Fresenius Medical Care Diagonal,
arcelona: F. Barbosa, M.  Chiné, S. Hurtado; CETIRSA, Terrassa:
. Llibre, A. Ruiz, M.  Serra, M.  Salvó, T. Poyuelo; Hospital Clínic,
arcelona: F. Maduell, M.  Carrera, N. Fontseré, M.  Arias, Josep
 Campistol,; Fresenius Medical Care Julio Verne, Barcelona: A.
erín, L. Ribera; Fundació Althaia, Manresa: JM. Galceran, J.
òdol, E. Moliner, A. Ramirez; Hospital Santa Tecla, Tarragona:
. Aguilera, M.  Alvarez; Diaverum Bonanova, Barcelona: B. de la
orre, M.  Molera; Diaverum IHB, Barcelona: J. Casellas, G. Martín;
undació Puigvert, Barcelona: E. Andres, E. Coll; Hospital Josep
rueta, Girona:  M.  Valles, C. Martínez; Hospital General, Vic:  E.
astellote; Diaverum, Mataró:  JM.  Casals, J. Gabàs, M. Romero;
ospital Universitari Bellvitge, Hospitalet:  A. Martinez-Castelao,
. Fulladosa; Hospital de Terrassa: M.  Ramirez-Arellano, M Ful-
uet; Diaverum Verge de Montserrat, Santa Coloma: A. Pelegrí, M.
l Manouari, N. Ramos; Centre Secretari Coloma, Barcelona: J. Bar-
olomé; Hospital de Figueres, R. Sans; Hospital Arnau de Vilanova,
leida: E. Fernández, F. Sarró; Hospital Santa Creu, Tortosa: T.
ompte; Diaverum Nephros, Barcelona: F. Marco,  R. Mauri; Clínica
irona: J. Bronsoms.
Clinical Trials Unit: JA. Arnaiz, H. Beleta, A. Pejenaute (UASP
armacología Clínica, Hospital Clínic Barcelona).
Statistical analysis: F. Torres, J. Ríos and J. Lara (Biostatistics
nit, School of Medicine, Universitat Autònoma de Barcelona;
iostatistics and Data Management Platform, IDIBAPS, Hospi-
al Clinic; Barcelona).
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